alexa National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population.
Haematology

Haematology

Journal of Blood Disorders & Transfusion

Author(s): Hutchison CA, Dasgupta I

Abstract Share this page

Abstract BACKGROUND: Heparin-induced thrombocytopoenia (HIT) type II is an antibody-mediated, drug-induced thrombocytopenia which is associated with significant morbidity and mortality. Several case reports and small series have described the occurrence of HIT type II in the haemodialysis population and the challenges associated with it. Some of these reports raise the possibility of a recent increase in prevalence of this condition. But to date, there has never been a large study to estimate the prevalence, demography or treatment options for this syndrome in the haemodialysis population. METHODS: The renal units in the UK were surveyed to establish the prevalence of HIT type II syndrome in the haemodialysis population. Demographic data for haemodialysis patients with HIT type II syndrome were gathered and current treatments assessed. RESULTS: Fifty responses from the 81 UK renal units surveyed were received. The combined population for these units was 13 682 patients on dialysis of whom 10 564 were on maintenance haemodialysis. The prevalence and incidence of HIT type II syndrome in the UK haemodialysis population were 0.26 and 0.32 per 100 patients, respectively. The mean age of the patients with HIT type II syndrome was 62 years (range 22-86), 52\% were females and 92\% were Caucasians. Only 17\% of patients have had complications of HIT syndrome. Thirty-six percent of renal units use danaparoid as anticoagulant of choice for patients on haemodialysis with HIT type II syndrome. CONCLUSION: This is the largest survey of HIT type II in the haemodialysis population to date. The prevalence is considerably lower (0.26 per 100 patients) than previous estimates, with only a minority of patients developing complications of the condition. Haemodialysis patients with HIT type II in the UK are predominantly treated with danaparoid. This article was published in Nephrol Dial Transplant and referenced in Journal of Blood Disorders & Transfusion

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords